Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enteral Vancomycin for C. diff Prophylaxis in Critically Ill Patients
NCT07221370Phase 3Recruiting
- Sponsor
- Riverside University Health System Medical Center
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vancomycin in Clostridioides difficile infection (CDI), sponsored by Riverside University Health System Medical Center. Started Oct 2024; status: recruiting.
02
Drugs
vancomycin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07221370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221370.